Hepatobiliary Oncology
Research activity includes unresectable intrahepatic cholangiocarcinoma and other bile duct cancer presentations involving liver-confined disease.
- Inoperable bile duct cancer
- Hepatic arterial infusion pump chemotherapy
- Systemic chemotherapy
The therapeutic emphasis is on combining regional liver-directed treatment with systemic regimens for advanced hepatobiliary malignancies.
Prostate Cancer
Clinical research also focuses on metastatic castration-resistant prostate cancer, a treatment-resistant form of advanced prostate carcinoma.
- Docetaxel-based therapy
- Radium-223
- Metastatic disease
This area reflects interest in treatment strategies for men with progressive mCRPC and skeletal or disseminated disease burden.
Combination Anticancer Therapy
The portfolio includes studies of combination chemotherapy and integrated modality treatment across solid tumors.
- GemOx
- FUDR/Dex
- Docetaxel combinations
These trials examine the use of multi-agent regimens in advanced cancer settings where disease control remains a major therapeutic need.
Radiopharmaceutical and Liver-Directed Treatment
Another area of interest is the use of Radium-223 alongside standard systemic therapy, together with hepatic arterial infusion approaches for liver-dominant tumors.
- Radiopharmaceutical therapy
- Liver-directed oncology
- Regional infusion therapy
These studies reflect a focus on targeted treatment delivery in solid tumor oncology.
